Johnson & Johnson (JNJ) reported mixed first-quarter 2017 earnings results on Tuesday.
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here is a look at five companies including Pfizer (PFE) that sport a favorable Zacks Rank and have a positive earnings ESP.
Pfizer, Inc. (PFE) missed earnings estimates in the fourth quarter.
PFE missed fourth quarter earnings which came in at 47 cents while our consensus called for EPS of 50 cents.
Pfizer Inc. (PFE) will be reporting fourth-quarter and full-year 2016 earnings results on Jan 31, before market open.
Pfizer, Inc. (PFE) announced positive top-line results from the comparative REFLECTIONS B538-02 study on its investigational compound, PF-06410293, a potential biosimilar to AbbVie Inc.'s (ABBV) Humira.
Pfizer, Inc. (PFE) announced positive top-line results from the comparative REFLECTIONS B538-02 study on its investigational compound, PF-06410293, a potential biosimilar of Humira approved for the treatment of patients with rheumatoid arthritis.
Pfizer's shares surpassed that of large-cap pharma industry in 2016. The stock rose 0.6% in 2016.
Cempra (CEMP) announced that it received a CRL from the FDA relating to its new drug applications for oral and intravenous formulation of candidate solithromycin.
Pfizer, Inc. (PFE) recently announced that its experimental biosimilar of Roche Holding AG's (RHHBY) breast cancer drug - Herceptin - has reached the primary endpoint in a pivotal study.
Pfizer Inc.'s (PFE) third-quarter adjusted earnings per share came in at 61 cents, a penny below the Zacks Consensus Estimate of 62 cents.
PFE missed third quarter earnings which came in at 61 cents while our consensus called for EPS of 62 cents
Pfizer Inc. (PFE) will be reporting third-quarter 2016 earnings on Nov 1, before market open.
The expected positive third-quarter performance by the broader Medical sector is something investors definitely need to muse on.
The Zacks Analyst Blog Highlights: AT&T, General Mills, Pfizer and Time Warner
The Zacks Analyst Blog Highlights: Pfizer, Novartis AG, Amgen, Merck and Momenta Pharmaceuticals
Given the current scenario of increased political, media and public pressure on drug pricing, it makes sense to zero in on companies that are in the biosimilars business.
Pfizer Inc. (PFE) announced that its Inflectra injection, a biosimilar version of Johnson & Johnson's (JNJ) blockbuster drug Remicade, will be available in the U.S. in late November.
Pfizer Inc. (NYSE: PFE) recently announced that it has entered into definitive agreement with ICU Medical (NASDAQ: ICUI) to sell its infusion systems business, which it had received via the acquisition of Hospira last year. The deal is expected to close in first quarter of 2017. The small medical device [...]